Targeted therapies for bone regeneration
We are commercializing a small molecule-based osteoinductive platform technology to develop bone growth products that activate a novel molecular pathway.
Discovered serendipitously, Zetagen'sTM products have the potential to transform the treatment of bone-related injuries, procedures and diseases to deliver better outcomes for patients, doctors and payors.
Initial data indicate this novel pathway has the potential to offer a suite of advantages not observed by other products on market, including:
Initial data show bone generation better than biologic growth factors
Inhibition of cancer growth via a known p21 mechanism
Down-regulation of osteoclasts reduces bone destruction
Our products will utilize small molecule components that are significantly more cost-effective to manufacture relative to biologic comparators
Components of our products have well-established clinical safety profiles
The technology has the potential for wider use compared to existing therapies due to its unique safety profile
We believe in identifying and pursuing optimal therapeutic solutions - no matter how unconventional - by building a learning organization that maximizes outcomes for people, investors and society.
Joe is a proven leader with a distinguished career in building and leading teams in rapid growth organizations within the spine & orthopedic industries. Recently, he was the Executive V.P., Sales for Life Spine. Prior to that, Joe was the Vice President of Sales for CoAlign and steered their acquisition by Stryker Spine. His first “Start-up” was NuVasive as their 5th hire in sales, held multiple positions of increasing responsibility including Senior Group Director, as sales grew from zero to +$750M during his 11+year tenure. Joe was the National Sales Mgr. for Pfizer / Leibinger, acquired by Stryker, and started his medical device career with U.S. Surgical. He serves as an Advisor & Board of Directors for a variety of orthopedic & spinal implant companies.
Bryan Margulies, PhD
CSO and Cofounder
Dr. Margulies was formerly an assistant professor of orthopedics, cell biology and pharmacology at SUNY-Upstate. His research focuses on stem cell modulation to promote bone formation in all practice areas including bone sarcoma. He obtained his PhD, MS and BS in bioengineering from Syracuse University and trained at the University of Pennsylvania in the College of Veterinary Medicine. Dr. Margulies was an NIH NRSA Fellow, a Mazess Student Fellow and has over 25 publications.
Nikhil Thakur, MD
Cofounder and Board Director
Dr. Thakur is the Director of the Spine Center at Lawrence General Hospital, a Harvard affiliate. He specializes in adult spine reconstructive surgery and has over a decade of orthopedic surgical experience. He has won multiple awards for his orthopedic research and has over 25 publications. Dr. Thakur received his MD from Geisel School of Medicine at Dartmouth and completed his fellowship training in trauma from Brown University and in spine surgery from Emory University.
We are grateful for the support we have received to date from several groups including: